High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011
Advertisement
Pfizer Inc said that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent (Irish Patent Number 60014) expires in November 2011.
"Today's decision is yet another affirmation of the strength of the intellectual property behind Lipitor," said Pfizer General Counsel Allen Waxman. "It also is an important outcome for Pfizer and other medical innovators who invest in high-risk research to develop life-saving medicines, and for the patients who benefit from those medicines."
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Recycled garnet sand as a source of scandium?

Scientists spy on lithium ions
Psychodynamic_psychotherapy

It looks like rubber but isn't - What goes on in a concentrated solution of circular polymers?
Out of REACH - New legislation threatens medicines
New material puts a twist in light
Electron filmed for first time ever
New Real-Time PCR Test for Chlamydia and Gonorrhea Receives CE Mark Certification
Tecan concludes the sale of the Sample Management activities to NEXUS Biosystems

Perovskite edges can be tuned for optoelectronic performance
Low-carbon energy transition requires more renewables than previously thought
